Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qun He

Showing results (471-480 of 473) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 473 results.
Chinese Medical Journal|October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical StudyYing Zheng, Guang-Yan Cai, Li-Qun He, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Journal of Integrative Medicine|February 16, 2021
Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trialJie Wu, Shu-Wei Duan, Hong-Tao Yang, et al.
Pageof 48

Showing results (471-480 of 473) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 473 results.
Chinese Medical Journal|October 21, 2017
Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical StudyYing Zheng, Guang-Yan Cai, Li-Qun He, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Journal of Integrative Medicine|February 16, 2021
Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trialJie Wu, Shu-Wei Duan, Hong-Tao Yang, et al.
Pageof 48